8-K filing — IRONWOOD PHARMACEUTICALS INC (IRWD)
Filed: 2026-08-06 AccNo: 0001104659-26-091625 Size: 485 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Ironwood Pharma Initiates Phase 3 STARS‑2 Trial Of Apraglutide In Short Bowel Syndrome With Intestinal Failure
– Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and Patient Care –– Dr. Silber, a Drug Development Veteran, Will Lead
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 14, 2026, 11:32 AM
- Checked
- Jul 14, 2026, 11:32 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M Est
Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2026 sales outlook from $450.000 million-$475.000 million to $460.000 million-$485.000 million vs $460.118 million estimate.
Read original at benzingaIronwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.36 by 13.89 percent. This is a 121.43 percent increase over earnings of $0.14 per
Read original at benzinga